Texas Attorney General Ken Paxton and Health Choice Alliance are accusing Eli Lilly of “incentivizing” providers in the state ...

There were early hopes that the then-incoming Trump administration would get the ball rolling, but that didn’t immediately materialize either. On Monday, however, President Donald Trump confirmed his ...

Its shares aren't exactly cheap at recent levels, though.

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has ...

Opinion: Former FDA chief counsel Daniel Troy says the Inflation Reduction Act's drug pricing negotiation program poses ...

Over the past year, senior officials at the health ministry have spoken about various plans – launching GP clinics for urban primary healthcare, forming a pharmacy network, and expanding the list of e ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

High drug prices demand serious solutions. While tariffs aim to address these issues head-on, they may not deliver the ...

Clover Health's tech-driven model faces short-term challenges but holds strong upside potential. Explore why analysts predict ...

It would be one thing to slap steep tariffs on prescription drugs from a rival country like China. But not on vital medicines from our allies.

New York hospitals that get discounted drugs through a controversial federal program are gearing up for a new pilot that they ...

Trump’s main effort, which he cited on August 3, centers on getting drugmakers to offer the same price in the US as they do ...